JP2022547558A5 - - Google Patents

Info

Publication number
JP2022547558A5
JP2022547558A5 JP2022515857A JP2022515857A JP2022547558A5 JP 2022547558 A5 JP2022547558 A5 JP 2022547558A5 JP 2022515857 A JP2022515857 A JP 2022515857A JP 2022515857 A JP2022515857 A JP 2022515857A JP 2022547558 A5 JP2022547558 A5 JP 2022547558A5
Authority
JP
Japan
Prior art keywords
item
approximately
compound
aqueous parenteral
crystal morphology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515857A
Other languages
English (en)
Japanese (ja)
Other versions
JP7719769B2 (ja
JP2022547558A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050511 external-priority patent/WO2021050956A1/en
Publication of JP2022547558A publication Critical patent/JP2022547558A/ja
Publication of JP2022547558A5 publication Critical patent/JP2022547558A5/ja
Priority to JP2025124956A priority Critical patent/JP2025137788A/ja
Application granted granted Critical
Publication of JP7719769B2 publication Critical patent/JP7719769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515857A 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその医薬組成物 Active JP7719769B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025124956A JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
US62/898,679 2019-09-11
PCT/US2020/050511 WO2021050956A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025124956A Division JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Publications (3)

Publication Number Publication Date
JP2022547558A JP2022547558A (ja) 2022-11-14
JP2022547558A5 true JP2022547558A5 (cg-RX-API-DMAC7.html) 2024-03-19
JP7719769B2 JP7719769B2 (ja) 2025-08-06

Family

ID=74866690

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022515860A Active JP7703518B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその製剤
JP2022515857A Active JP7719769B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその医薬組成物
JP2025063311A Pending JP2025096427A (ja) 2019-09-11 2025-04-07 抗ウイルスプロドラッグ及びその製剤
JP2025124956A Pending JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022515860A Active JP7703518B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025063311A Pending JP2025096427A (ja) 2019-09-11 2025-04-07 抗ウイルスプロドラッグ及びその製剤
JP2025124956A Pending JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Country Status (18)

Country Link
US (3) US20220323476A1 (cg-RX-API-DMAC7.html)
EP (2) EP4028019A4 (cg-RX-API-DMAC7.html)
JP (4) JP7703518B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220066303A (cg-RX-API-DMAC7.html)
CN (4) CN119462802A (cg-RX-API-DMAC7.html)
AU (4) AU2020346907B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004424A2 (cg-RX-API-DMAC7.html)
CA (2) CA3150467A1 (cg-RX-API-DMAC7.html)
CL (4) CL2022000587A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022005128A2 (cg-RX-API-DMAC7.html)
CR (3) CR20260001A (cg-RX-API-DMAC7.html)
DO (2) DOP2022000055A (cg-RX-API-DMAC7.html)
IL (5) IL319709A (cg-RX-API-DMAC7.html)
MX (4) MX2022002897A (cg-RX-API-DMAC7.html)
PE (2) PE20221037A1 (cg-RX-API-DMAC7.html)
PH (2) PH12022550528A1 (cg-RX-API-DMAC7.html)
UA (1) UA130229C2 (cg-RX-API-DMAC7.html)
WO (2) WO2021050956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) * 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
US20240190878A1 (en) * 2021-03-16 2024-06-13 The Scripps Research Institute Antiviral prodrugs of etv and formulations thereof
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
TW202500140A (zh) * 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物
FI132042B1 (en) 2024-01-17 2026-05-04 Metso Finland Oy Precipitation of calcium compounds in liquid extraction systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283067A (en) 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5192749A (en) 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US20130244966A1 (en) 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
FR3053281B1 (fr) 2016-06-30 2020-03-27 Banque De France Procede de fabrication d'un document de securite presentant un signe de securite a contraste de brillance
US10185393B2 (en) 2017-04-03 2019-01-22 Facebook Technologies, Llc Waveguide display with spatially switchable grating
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
TW202500140A (zh) 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物

Similar Documents

Publication Publication Date Title
JP7719769B2 (ja) 抗ウイルスプロドラッグ及びその医薬組成物
JP2023543059A5 (cg-RX-API-DMAC7.html)
JP2022547978A5 (cg-RX-API-DMAC7.html)
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2004509061A5 (cg-RX-API-DMAC7.html)
RU2002120922A (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
KR20150093819A (ko) 약제 조성물
JP2008514732A5 (cg-RX-API-DMAC7.html)
ES2324009B1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP2022527556A5 (cg-RX-API-DMAC7.html)
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2024507788A5 (cg-RX-API-DMAC7.html)
JP2018532797A5 (cg-RX-API-DMAC7.html)
JP2007501284A5 (cg-RX-API-DMAC7.html)
JP2024503723A5 (cg-RX-API-DMAC7.html)
WO2014035945A1 (en) Pharmaceutical compositions
WO1996038173A1 (en) Brain edema inhibitor
JP2022548652A (ja) コアタンパク質アロステリックモジュレータを使用してhbv感染を処置する方法
JP2022521119A5 (cg-RX-API-DMAC7.html)
JP2021501202A5 (cg-RX-API-DMAC7.html)
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
JP2022547324A5 (cg-RX-API-DMAC7.html)
CA3132095A1 (en) Capsid assembly modulator solid formulation
JP2021523129A5 (cg-RX-API-DMAC7.html)